• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Bruker Corporation

    5/19/25 8:00:04 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email
    DEFA14A 1 brkr_defa_14a_letter_v2.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material under §240.14a-12

    Bruker Corporation

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

    The following communication was first distributed to certain stockholders of Bruker Corporation on or after May 19, 2025.

     

     

     


     

    Your Vote Counts! BRUKER CORPORATION 2023 Annual Meeting Vote by June 6, 2023 11:59 PM ET BRUKER CORPORATION C/O AMERICAN STOCK TRANSFER 6201 FIFTEENTH AVENUE BROOKLYN, V09041-P90080NY 11219 You invested in BRUKER CORPORATION and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 7, 2023. Get informed before you vote View the Notice and Proxy Statement, Annual Report and Form of Proxy online OR you can receive a

    free paper

     

     

     

     

    img170272345_0.jpg

     

    May 19, 2025

    Dear Stockholder:

    We are supplementing our 2025 Proxy to include additional information concerning our 2026 Incentive Compensation Plan, which we refer to as our 2026 Plan, and seek your independent assessment and approval of Proposal 4 at our Annual Stockholders Meeting on May 29, 2025.

    Supplementary Information concerning Proposal 4, adoption of 2026 Incentive Compensation Plan

    The 2026 Plan was approved by the Board of Directors including our independent Compensation Committee

    Bruker’s Board of Directors adopted the 2026 Plan on February 18, 2025, upon the recommendation of our independent Compensation Committee, subject to stockholder approval at the 2025 Annual Meeting. If approved by our stockholders, the 2026 Plan will become effective on February 19, 2026, which will be the date immediately following expiration of the Bruker Corporation 2016 Incentive Compensation Plan, which we refer to as our 2016 Plan.

    The 2026 Plan, if approved by stockholders, will replace the expiring 2016 Plan. The Company will be unable to issue equity to its employees, leadership, or Board if the 2026 Plan is not approved.

    Our 2016 Plan expires in February 2026 and the 2026 Plan will replace the 2016 Plan at that time. The terms of the 2026 Plan are largely consistent with our 2016 Plan. If the 2026 Plan is not approved, we will not be able to grant equity compensation to our employees and directors, an important component of our compensation program. Equity compensation is needed to attract and retain employees in the competitive labor markets in which we compete for talent and to align employee and director interests with those of our stockholders. If the 2026 Plan is not approved, the effect will be to cease all equity-based awards to employees, leadership, and the Board after the 2016 Plan expires and impact their long-term alignment with our stockholders. In addition, we may be required to offer additional cash compensation to our employees in lieu of equity compensation to remain competitive, which would reduce our cash resources that would otherwise be available for other business initiatives.

     

     


    Key elements of the 2026 Plan are consistent with incentive compensation plans of our peers

    The 2026 Plan cost is aligned with peer practice. Our total overhang1 of 8.4% approximates the peer 2023 overhang 50th percentile (7.1%). Furthermore, the total cost (shareholder value transfer) of the 2026 Plan is reasonable at 8.12%, which is below the Institutional Shareholder Services (“ISS”), a proxy advisory firm, benchmark of 9.64%.

    Assuming approval of the 2026 Plan, our available pool of approximately 11 million shares of common stock (7.3% of total shares outstanding) would be comparable to or below that of many of our peers at the time of their last share requests.

    The Company has a track record of prudently granting equity to employees, leadership, and the Board

    We have demonstrated a track record of prudently utilizing equity. Of the 9,500,000 shares originally approved by our stockholders for grant under the 2016 Plan, approximately 5,000,000 shares remain available for issuance, most of which would expire in February 2026 if the 2026 Plan is not approved. Our three-year average burn rate2 of 0.31% is below the peer 25th percentile (0.47%). ISS calculates our three-year average value-adjusted burn rate to be 0.27%, which is significantly lower than the ISS benchmark of 5.94% and the reported median of 3.61%.

    The 2026 Plan includes many stockholder-friendly provisions, consistent with the 2016 Plan

    The 2026 Plan includes several provisions that are considered to be stockholder friendly, including (i) no repricing without stockholder approval, (ii) no evergreen provision for the share reserve, (iii) no liberal share recycling, and (iv) a minimum one-year vesting requirement.

    The 2026 Plan is supported by Glass Lewis & Co. (“Glass Lewis”), another proxy advisory firm, but ISS issued a voting recommendation against the 2026 Plan

    Glass Lewis issued a voting recommendation supporting Proposal 4. ISS recently issued a voting recommendation against Proposal 4. In its report, ISS gives three primary reasons for its recommendation: (1) the cost of the proposed 2026 Plan is deemed excessive, (2) the estimated duration of available and proposed shares exceeds six years, and (3) the 2026 Plan allows broad discretion to accelerate vesting. We respectfully disagree with ISS’s analysis of Proposal 4 for the following reasons:

    •
    As noted above, the cost and duration of the 2026 Plan is consistent with that of comparable peer plans.
    •
    Board discretion to accelerate vesting of grants under the 2026 Plan is a useful tool that allows necessary flexibility to address circumstances that arise, such as an employee’s retirement, death or disability. This flexibility is commonly included in equity plans in our industry. For example, based on ISS research, only 12% of companies in the Russell 3000 limit their board’s ability to accelerate vesting to only death or disability. We do not believe that this factor will have a negative impact on the 2026 Plan or our stockholders.

     


    1 Overhang is defined as (options and RSUs outstanding + current pool + new pool) divided by shares of common stock outstanding.

    2 Burn rate is defined as options and RSUs granted divided by weighted average shares of common stock outstanding.

     

     


    The Bruker Board of Directors continues to unanimously recommend that our stockholders vote “FOR” the adoption of the 2026 Plan in Proposal 4.

    Whether or not you plan to attend the 2025 Annual Meeting, we encourage you to read the proxy statement and this supplementary information and submit your proxy or voting instructions as soon as possible. If you have already returned your proxy card or provided voting instructions to your broker, you do not need to take any action unless you wish to change your vote. Information regarding how to vote your shares and revoke previously submitted proxies is available in the proxy statement.

     

    Sincerely,

    Vice President, Corporate Human Resources Executive Vice President, Chief Financial Officer


     

     

     

     


    Get the next $BRKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    12/10/2025$60.00Peer Perform → Outperform
    Wolfe Research
    12/9/2025$40.00Sell
    Goldman
    11/20/2025$60.00Buy
    Rothschild & Co Redburn
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    More analyst ratings

    $BRKR
    SEC Filings

    View All

    Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    2/12/26 7:00:26 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - BRUKER CORP (0001109354) (Filer)

    1/12/26 12:00:24 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    12/9/25 10:10:52 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bruker Reports Fourth Quarter and Full Year 2025 Financial Results

    Q4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically Q4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS of $0.59 FY25 revenues of $3.44 billion, up ~2% yoy, down ~4% organically FY25 GAAP diluted loss per share of $(0.15); non-GAAP diluted EPS of $1.83 Bruker initiates FY26 guidance: Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind Bruker Corporation (NASDAQ:BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker's Presid

    2/12/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC

    New iNTApharma system enables rapid, native‑state size and concentration measurements with single‑particle sensitivity for viral, vesicle, and nanoscale bioparticle workflows Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticle populations without labeling or chemical modifications.

    2/9/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration

    At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enables lab managers to operationalize autonomous, AI‑orchestrated experimentation through vendor‑agnostic integration that unites modular precision automation, scientific analysis and lab management software, complete lab digitization a

    2/9/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Laukien Frank H bought $100,043 worth of shares (2,608 units at $38.36), increasing direct ownership by 0.01% to 38,462,171 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    6/9/25 4:15:11 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    3/11/25 4:11:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    2/19/25 4:23:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $98,400 worth of shares (2,000 units at $49.20) (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    1/16/26 4:15:05 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 7,000 shares at a strike of $22.19 and sold $385,000 worth of shares (7,000 units at $55.00) (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    1/13/26 4:15:06 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Phillips Jack

    3 - BRUKER CORP (0001109354) (Issuer)

    1/9/26 6:19:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bruker upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Bruker from Peer Perform to Outperform and set a new price target of $60.00

    12/10/25 9:02:11 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Bruker with a new price target

    Goldman initiated coverage of Bruker with a rating of Sell and set a new price target of $40.00

    12/9/25 8:43:14 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rothschild & Co Redburn initiated coverage on Bruker with a new price target

    Rothschild & Co Redburn initiated coverage of Bruker with a rating of Buy and set a new price target of $60.00

    11/20/25 8:06:38 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/14/24 1:28:29 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/13/24 6:01:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/12/24 11:54:03 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Financials

    Live finance-specific insights

    View All

    Bruker Reports Fourth Quarter and Full Year 2025 Financial Results

    Q4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically Q4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS of $0.59 FY25 revenues of $3.44 billion, up ~2% yoy, down ~4% organically FY25 GAAP diluted loss per share of $(0.15); non-GAAP diluted EPS of $1.83 Bruker initiates FY26 guidance: Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind Bruker Corporation (NASDAQ:BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker's Presid

    2/12/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Quarterly Preferred Stock Dividend

    Bruker Corporation (NASDAQ:BRKR, BRKRP)) today announced that its Board of Directors ("Board") has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock Dividend"). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 2026. About Bruker Corporation – Leader of the Post-Genomic Era Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's hi

    2/5/26 4:05:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Date and Time of Fourth Quarter 2025 Earnings Release and Webcast

    Bruker Corporation (NASDAQ:BRKR) today announced it will report fourth quarter and fiscal year 2025 financial results before market opening on Thursday, February 12, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q4 2025 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-43

    2/5/26 8:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    View All

    Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

    ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

    4/23/25 6:15:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

    Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

    4/4/24 8:11:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials